drugset

drugset / Trial / NCT00191412

A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver

NCT00191412 ↗

Phase 2 Completed 41 enrolled Eli Lilly and Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.

Timeline

Start: 2005-01
Primary completion: —
Completion: 2006-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pemetrexed	Small molecule	—	—

Indications